Abdel -Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013; 121(18):3563… [630841]

182 Bibliografie

Abdel -Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of
acute myeloid leukemia. Blood. 2013; 121(18):3563 -3572
Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel
FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113(4):983 –8
Adriaansen HJ, te Boekhorst PAW, Hagemeijer AM, van der Schoot CE, Delwel HR, van Dongen
JJM. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(1 6)(p13q22)
exhibits a specific immunophenotype with CD2 expression. Blood. 1993;81(11):3043 -3051.
Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid
leukemia: evaluation of transplantation as initial therapy or f ollowing induction chemotherapy. Blood.
1997;89(7):2578 -2585.
Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;
107(9):3481 -3485.
Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloi d
leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135(2):165 -173.
Appelbaum FR, Gundacker H, Head DR, et al Age and acute myeloid leukemia. Blood
2006; 107:3481 -3485.
Arber DA, Orazi A, Hasserjian R , Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the
World Health Organization classification of myeloid neoplasms and acute leukemia Blood
2016; 127(20):2391 -2405.
Arlin Z, Case DC Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with
mitoxan trone or daunorubicin in previously untreated adult patients with acute nonlymphocytic
leukemia (ANLL). Leukemia. 1990;4(3):177 -183.
Artz AS, Pollyea DA, Kocherginsky M, et al. Performance status and comorbidity predict transplant –
related mortality after a llogeneic hematopoietic cell transplantation. Biol. Blood. Marrow. Transplant.
2006; 12:954 –964.
Ashkan E, Maria R. Baer. Acute myeloid leukemia in adults. Greer JP, Arber DA, Glader B, List AF,
Means RT, Paraskevas F, Rodgers GM, editors, Wintrobe‟s Clin ical Hematology 13th Edition
2015:3602 -3606;
Ashkan Emadi and Maria R. Baer. Acute myeloid leukemia in adults. Greer JP, Arber DA, Glader B,
List AF, Means RT, Paraskevas F, Rodgers GM, editors, Wintrobe‟s Clinical Hematology 13th Edition
2015:3602 -3642 .
Ayatollahi H , Shajiei A, Sadeghian MH , Sheikhi M , Yazdandoust E , Ghazanfarpour M et al
Prognostic Importance of C -KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A
Systematic Review Hematol Oncol Stem Cell Ther. 2017;10(1):1 -7
Bacher U, Haferlach T, Schoch C, et al. Implication of NRAS mutations in AML: a study of 2502
patients. Blood 2006; 107:3847 –3853.
Bacher U, Kern W, Schnittger S, Hiddemann W, Haferlach T, Schoch C. Population -based ag e-
specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica.
2005;90(11):1502 -1510.

183 Bacher U, Schnittger S, Macijewski K, et al. Multilineage dysplasia does not influence prognosis in
CEBPA -mutated AML, supporting the WHO propos al to classify these patients as a unique entity.
Blood. 2012;119(20):4719 -4722.
Bacher U , Haferlach C, Kern W, Haferlach T and Schnittger S. Prognostic relevance of FLT3 -TKD
mutations in AML: the combination matters – an analysis of 3082 patients. Bloo d 2008;111:2527 -2537.
Baer MR, Barcos M, Farrell H, Raza A, Preisler HD. Acute myelogenous leukemia with leukemia
cutis. Eighteen cases seen between 1969 and 1986. Cancer 1989;63(11):2192 -2200.
Baer MR, Stewart CC, Lawrence D, et al. Expression of the ne ural cell adhesion molecule CD56 is
associated with short remission duration and survival in acute myeloid leukemia with
t(8;21)(q22;q22). Blood. 1997;90(4):1643 -1648.
Baer MR. Management of unusual presentations of acute leukemia. Hematol Oncol Clin North Am
1993;7(1):275 -292.
Barba P, Pinana JL, Martino R, Valcarcel D, Amoros A, Sureda A, Briones J, Delgado J, Brunet S,
Sierra J. Comparison of two pretransplant predictive models and a flexible HCT -CI using different cut
points to determine low -, intermedi ate-, and high – risk groups: the flexible HCT -CI is the best
predictor of NRM and OS in a population of patients undergoing allo -RIC. Biol Blood Marrow
Transplant 2010;16 : 413 -420
Bashir Q, William BM, Garcia -Manero G, de Lima M. Epigenetic therapy in allogeneic hematopoietic
stem cell transplantation. Rev Bras Hematol Hemoter. 2013; 35(2):126 -133.
Bayer MR and Greer JR. Acute myeloid leukemia in adults. Greer JP, Foreste r J, Rodgers GM,
Paraskevas F, Glader B, Glader B, Arber DA, Means RM editors, Wintrobe‟s Clinical Hematology
12th Edition 2008: 1844.
Behringer B, Pitako JA, Kunzmann R, et al. Prognosis of older patients with acute myeloid leukemia
receiving either in duction or noncurative treatment: a single -center retrospective study. Ann Hematol
2003;82: 381 -9.
Bejar R, Stevenson K, Abdel -Wahab O, et al. Clinical effect of point mutations in myelodysplastic
syndromes. N Engl J Med. 2011;364(26):2496 -2506.
Bejar R, S tevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with
myelodysplastic syndrome after hematopoietic stem -cell transplantation. J Clin Oncol.
2014;32(25):2691 -2698.
Bejar R, Stevenson KE, Caughey BA, et al. Validation of a pr ognostic model and the impact of
mutations in patients with lower -risk myelodysplastic syndromes. J Clin Oncol. 2012; 30(27):3376 –
3382.
Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute
leukemias. European Group f or the Immunological Characterization of Leukemias (EGIL). Leukemia.
1995;9(10):1783 -1786.
Bennet JM, Catovsky D, Daniel M -T, et al. Proposal for the recognition of minimally differentiated
acute myeloid leukaemia (AML -M0). Br J Haematol. 1991;78(3):325 -329.
Bennett JM et al. Proposed revised criteria for the classification of acute myeloid leukemia. Annals of
Internal Medicine 1985;103:626 -9.
Berman E, Arlin ZA, Gaynor J, et al. Comparative trial of cytarabine and thioguanine in combination
with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of
the L -16M protocol. Leukemia. 1989;3(2):115 – 121.

184 Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine
arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute
myelogenous leukemia. Blood. 1991;77(8):1666 -1674.
Bhatia S. Therapy -related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013;
40(6):666 -675.
Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute
leukemia never achieving remission with chemotherapy. Blood. 1992;80(4):1090 -1093.
Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood.
1990;7 5(1):27 -32.
Bishop JF, Matthews JP, Young GA, et al. Randomized study of high -dose cytarabine in induction in
acute myeloid leukemia. Blood. 1996; 87(5):1710 -1717.
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequenc y of
prolonged remission duration after high -dose cytarabine intensification in acute myeloid leukemia
varies by cytogenetic subtype. Cancer Res 1998;58:4173 -9.
Boissel N, Renneville A, Leguay T, et al. Dasatinib in high -risk core binding factor acute mye loid
leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.
Haematologica. 2015;100(6): 780 -785.
Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with
distinct cytogenetic subgroups bu t does not influence outcome in patients younger than 60 years.
Blood 2005; 106:2113 –2119
Brands -Nijenhuis AV , Labopin M , Schouten HC , Volin L , Socie G, Cornelissen JJ et al. Monosomal
karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with
allogeneic hematopoietic stem -cell transplantation in first complete remission: a retrospective survey
on behalf of the ALWP of the EBMT. Haematologica. 2016;101(2):248 -55
Breems DA, Van Putten WL, De Gree f GE, et al. Monosomal karyotype in acute myeloid leukemia: a
better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791 -4797.
Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute
myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969 -1978.
Breems DA, van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid
leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol.
2008;26(29):4 791-4797
Buchner T, Berdel WE, Haferlach C, et al. Age -related risk profile and chemotherapy dose response in
acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin
Oncol. 2009;27(1):61 -69.
Buchner T, Berdel WE, Hidd emann W. Priming with granulocyte colony stimulating factor – relation
to high -dose cytarabine in acute myeloid leukemia [comment]. N Engl J Med. 2004;350(21): 2215 –
2216.
Buchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course
of high -dose cytarabine plus mitoxantrone and post -remission therapy by either autologous stem -cell
transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol.
2006;24(16):2480 -2489.
Buchner T, Hiddemann W, Berdel W E, et al. 6 -thioguanine, cytarabine, and daunorubicin (TAD) and
high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either
prolonged maintenance by reduced monthly TAD or TAD -HAM -TAD and one course of intensive

185 consolidati on by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia
(AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21(24):4496 –
4504.
Bullinger L, Dohner H Genetics guided therapeutic approaches in acute myeloid leukemia
Hematology Education: the education program for the annual congress of the European Hematology
Association 2013;7:30 -40
Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of addition of autologous
bone -marrow transplantat ion to intensive chemotherapy for acute myeloid leukaemia in first
remission: results of MRC AML 10 trial. Lancet. 1998;351(9104):700 -708.
Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all -trans retinoic acid
to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia:
overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
Blood. 2010;115(5): 948 -956.
Burnett AK, Hills RK, Milligan D, et al. Ide ntification of patients with acute myeloid leukemia who
benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol.
2011;29(4):369 -377.
Burnett AK, Milligan D, Prentice AG, et al. A comparison of low -dose cytarabine an d hydroxyurea
with or without all -trans retinoic acid for acute myeloid leukemia and high -risk myelodysplastic
syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114 -1124.
Burnett AK, Russell N, Hills RK, et al. A compari son of single -dose gemtuzumab ozogamicin 3
mg/m2 and 6 mg/m2 combined with induction chemotherapy in younger patients with AML: data from
the UK NCRI AML17 trial [abstract]. Blood. 2014;124(21). Abstract 2308.
Burnett AK, Russell NH, Hills RK, et al. Addit ion of gemtuzumab ozogamicin to induction
chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;
30(32):3924 -3931.
Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with
acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol.
2013;31(27):3360 -3368.
Burnett AK, Russell NH, Hills RK, et al; UK NCRI AML Study Group. A randomized comparison of
daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction : results from the UK NCRI AML17 trial in
1206 patients. Blood. 2015;125(25): 3878 -3885.
Burnett AK, Russell NH, Hills RK; United Kingdom National Cancer Research Institute Acute
Myeloid Leukemia Study Group. Higher daunorubicin exposure benefits FLT3 muta ted acute myeloid
leukemia. Blood. 2016;128(3): 449 -452
Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in
patients with acute myeloid leukaemia at different risk of relapse: results of the UK MRC AML 10
trial. B r J Haematol. 2002;118(2):385 -400.
Buyse M, Squifflet P, Lange BJ, et al. Individual patient data meta -analysis of randomized trials
evaluating IL -2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood.
2011;117(26):7007 -7013.
Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have
superior failure -free and overall survival when repetitive cycles of high -dose cytarabine are
administered. J Clin Oncol. 1999;17(12): 3767 -3775

186 Byrd JC, Rupp ert AS, Mrozek K, et al. Repetitive cycles of high -dose cytarabine benefit patients with
acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin
Oncol. 2004;22(6):1087 -1094
Byrd JC, Mrozek K, Dodge RK, et al. Pretre atment cytogenetic abnormalities are predictive of
induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo
acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood
2002; 100(13):432 5-4336
Cairoli R , Beghini A, Grillo G , Nadali G , Elice F , Ripamonti CB Prognostic impact of c -KIT
mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006; 107(9):3463 -8
Cancer Genome Atlas Research Network. Genomic and Epige nomic Landscapes of Adult De Novo
Acute Myeloid Leukemia. N Engl J Med. 2013;368(22):2059 -74
Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or
allogeneic bone marrow transplantation in the management of acute myeloi d leukemia in first
remission. N Engl J Med. 1998;339(23):1649 – 1656.
Cassileth PA, Lee SJ, Litzow MR, et al. Intensi fied induction chemotherapy in adult acute myeloid
leukemia followed by high -dose chemotherapy and autologous peripheral blood stem cell
transplantation: an Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma.
2005;46(1):55 -61.
Cassileth PA , Sylvester LS , Bennett JM , Begg CB . High peripheral blast count in
adult acute myelogenous leukemia is a primary risk factor for CNS leukemia J Clin Oncol. 1988
Mar;6(3):495 -8
Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients
with de -novo acute myeloid leukaemia (ALFA -0701): a randomised, open -label, phase 3 study.
Lancet. 2012;379(9825):1508 -1516.
Chan SM, Majeti R: Role of DNMT3A, TET2, and IDH -1/2 mutations in pre -leukemic stem cells in
acute myeloid leukemia. Int J Hematol 2013; 98:648.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin
Epidemiol. 1994;47(11):1245 -1251.
Chen YB, Shuli L, Andrew LA, et al. Phase I trial of maintenance sorafenib after allogeneic
hematopoietic stem cell t ransplantation for patients with FLT3 -ITD AML [abstract]. Blood.
2014;124(21). Abstract 671.
Cherry AM, Slovak ML, Campbell LJ, Chun K, Eclache V, Haase D, et al. Will a peripheral blood
(PB) sample yield the same diag – nostic and prognostic cytogenetic d ata as the concomitant bone
marrow (BM) in myelodysplasia? Leuk Res. 2012;36(7):832 -40.
Cheson BD, Bennett JM, Kopecky Kj et al. Revised recommendations of the International Working
Group for Diagnosis, Reporting Standards for Therapeutic Trials in acute m yeloid leukemia J Clin
Oncol 2003; 21:4642 -4649.
Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis,
Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic
Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for
Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for
Therapeutic Trials in Acute Myeloid Leukemia [published correction appears in J Clin O ncol.
2004;22(3):576]. J Clin Oncol. 2003;21(24):4642 -4649.

187 Chevallier P, Labopin M, Turlure P, et al. A new Leukemia Prognostic Scoring System for
refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia.
2011;25(6):939 -944.
Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute
myeloid leukemia patients with intermediaterisk cytogenetics. Blood. 2011;118(14):3803 -3810.
Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute
myeloid leukemia with additional sex comb -like 1 (ASXL1) mutations. Blood. 2010;116(20):4086 –
4094.
Christiansen DH, Andersen MK, PedersenBjergaard J. Mutations with loss of heterozygosity of p53
are common in therapyrelated myelod ysplasia and acute myeloid leukemia after exposure to alkylating
agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor
prognosis. J Clin Oncol. 2001;19(5):1405 -1413.
Churpek J, Marquez R, Neistadt B, et al. Inher ited mutations in cancer susceptibility genes are
common among survivors of breast cancer who develop therapy -related leukemia. Cancer.
2016;122(2):304 -311.
Churpek JE, Godley LA. How I diagnose and manage individuals at risk for inherited myeloid
malignan cies. Blood. 2016;128(14):1800 – 1813.
Churpek JE, Larson RA. The evolving challenge of therapy -related myeloid neoplasms. Best Pract Res
Clin Haematol. 2013;26(4):309 -317.
Cleven AH, Nardi V, Ok CY, et al. High p53 protein expression in therapy -related m yeloid neoplasms
is associated with adverse karyotype and poor outcome. Mod Pathol. 2015;28(4): 552 -563.
Cornelissen JJ, van Putten WLJ, Verdonck LF, et al. Results of a HOVON/SAKK donor versus
nodonor analysis of myeloablative HLA -identical sibling stem cell transplantation in first remission
acute myeloid leukemia in young and middleaged adults: benefits for whom? Blood. 2007;
109(9):3658 -3666.
Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood.
2008;111(8):3941 -3967
Damm F, Heuser M, Morgan M, et al. Integrative prognostic risk score in acute myeloid leukemia
with normal karyotype. Blood. 2011;117(17): 4561 -4568.
Damm F, Markus B, Thol F, et al. TET2 mutations in cytogenetically normal acute myeloid leukemia:
clinical implications and evolutionary patterns. Genes Chromosomes Cancer. 2014;53(10):824 -832.
Daver N, Cortes J, Ravandi F, et al. Secondary mutations as mediators of resistance to targeted therapy
in leukemia. Blood. 2015;125(21): 3236 -3245.
de Labarthe A, Pau tas C, Thomas X, et al; Acute Leukemia French Association. Allogeneic stem cell
transplantation in second rather than first complete remission in selected patients with good -risk acute
myeloid leukemia. Bone Marrow Transplant. 2005;35(8):767 -773.
Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamicin to chemotherapy
improves event -free survival but not overall survival of AML patients with intermediate cytogenetics
not eligible for allogeneic transplantation: results of the GOELAMS AML 20 06 IR study [abstract].
Blood. 2011;118(21). Abstract 79.
Deschler B, Lübbert M: Acute myeloid leukemia: epidemiology and etiology: Cancer 107. 2006:
2099 -2107

188 Diaz -Beya M, Rozman M, Pratcorona M, et al. The prognostic value of multilineage dysplasia in de
novo acute myeloid leukemia patients with intermediate -risk cytogenetics is dependent on NPM1
mutational status. Blood. 2010;116(26): 6147 -6148.
Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W, et al. Mutation analysis for
RUNX1, MLL -PTD , FLT3 -ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.
Leukemia. 2010;24(8):1528 –32.
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T et al. Diagnosis and
management of acute myeloid leukemia in adults: 2017 ELN Recommendatio ns from an International
Expert Panel, Blood 2017; 129(4): 424 –447
Dohner H, Estey EH, Amadori S, Appelbaum FR, B uchner T, Burnett AK et al. Diagnosis and
management of acute myeloid leukemia in adults: recommendations from an international expert
panel, o n behalf of the European LeukemiaNet Blood 2010;115(3):453 -74
Dohner H, Seymour JF, Butrym A, et al. Overall survival in older patients with newly diagnosed acute
myeloid leukemia (AML) with 30% bone marrow blasts treated with azacitidine by cytogenetic ri sk
status: Results of the AZA -AML – 001 study [abstract]. Blood. 2014;124(21). Abstract 621.
Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia N Engl J Med 2015;
373(12):1136 -1152
Dohner K , Paschka P . Intermediate -risk acute myeloid leukemia therapy: current and fut ure.
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):34 -43
Dombret H and Gardin C. An update of current treatments f or adult acute myeloid leukemia. Blood.
2016;127(1):53 -61.
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional
care regimens in older patients with newly diagnosed AML with .30% blasts. Blood. 2015;126(3):291 –
299
Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene
mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical
outcome. J Clin Oncol. 2010;28(4): 570 -577.
Duval M, K lein JP, He W, et al. Hematopoietic stem -cell transplantation for acute leukemia in relapse
or primary induction failure. J Clin Oncol. 2010;28(23):3730 -3738.
Ebstein W: Ueber die acute Leukamie und Pseudoleukamie. Dtsch Arch Klin Med 44:343, 1889
El Hajj H, Dassouki Z, Berthier C, et al. Retinoic acid and arsenic trioxide trigger degradation of
mutated NPM1, resulting in apoptosis of AML cells. Blood. 2015;125(22):3447 -3454.
Ellison RR, Holland JF, Weil M, et al: Arabinosyl cytosine: A useful agent in the treatment of acute
leukemia in adults. Blood 33:507,1968.
Elonen E, Almqvist A, Ha¨nninen A, et al. Comparison between four and eight cycles of intensive
chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
Leuke mia. 1998;12(7):1041 -1048.
Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced -intensity conditioning
(RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute
myeloid leukemia (AML) and h igh-risk myelodysplastic syndrome (MDS). Blood. 2007; 109(4):1395 –
1400.
Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894 -1907.

189 Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for
evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous
leukemia. Blood. 1996;88(2):756.
Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia
with excess blasts, refractory ane mia with excess blasts in transformation, or acute myeloid leukemia
[AML]) on outcome of AML -type chemotherapy. Blood. 1997;90(8):2969 -2977.
Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin
Oncol. 2007;25(14):1908 -1915 .
Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin ara -C–, fludarabine araC –, and
topotecan ara -C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory
anemia with excess blasts in transformation, or refractory ane mia with excess blasts. Blood.
2001;98(13):3575 -3583.
Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in
myelodysplasia and acute myeloid leukemia. Leukemia. 2013;27(9):1803 -1812.
Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;
14(3):476 -479.
Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are
independent in older cancer patients. J. Clin. Oncol. 1998; 16:1582 -1587
Falini B, Macijewsk i K, Weiss T, et al. Multilineage dysplasia has no impact on biologic,
clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood.
2010;115(18):3776 -3786.
Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in a cute myelogenous leukemia with
a normal karyotype. N Engl J Med. 2005; 352(3):254 -266.
Falini B, Mecucci C, Tiacci E, et al , Gimema Acute Leukemia Working Party. Cytoplasmic
nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;
352:254 –266.
Farag SS, Archer KJ, Mro´zek K, et al. Pretreatment cytogenetics add to other prognostic factors
predicting complete remission and long -term outcome in patients 60 years of age or older with acute
myeloid leukemia: results from Cancer an d Leukemia Group B 8461. Blood. 2006;108(1):63 -73.
Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P.
The hematopoietic cell transplantation comorbidity index (HCT -CI) predicts clinical outcomes in
lymphoma an d myeloma patients after reduced – intensity or non -myeloablative allogeneic stem cell
transplantation. Leukemia 2009;23: 1131 -1138
Felicitas Thol , Richard F. Schlenk , Michael Heuser and Arnold Ganser. How I treat refractory and early
relapsed acute myeloid leukemia . Blood 2015; 126(3):319 -327
Fenaux P, Mufti GJ, Hellstrom -Lindberg E, et al. A zacitidine prolongs overall survival compared with
conventional care regimens in elderly patients with low bone marrow blast count acute myeloid
leukemia. J Clin Oncol. 2010;28(4): 562 -56.
Fenaux P, Mufti GJ, Hellstrom -Lindberg E, et al; International Vida za High -Risk MDS Survival Study
Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of
higher -risk myelodysplastic syndromes: a randomised, open -label, phase III study. Lancet Oncol.
2009;10(3):223 -232.
Fernande z HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N
Engl J Med. 2009;361(13): 1249 -1259.

190 Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N
Engl J Med. 2009;361(13): 12 49-1259.
Ferraris AM, Broccia G, Meloni T, et al: Clonal origin of cells restricted to monocytic differentiation
in acute nonlymphocytic leukemia. Blood 1984; 64:817.
Fialkow PH, Singer JW, Adamson JW, et al: Acute nonlymphocytic leukemia. Heterogeneity of stem
cell origin. Blood 1981;57:1068.
Figueroa ME, Abdel -Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a
hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer
Cell. 2010;18(6): 553 -567.
Friedreich N: Ein neuer Fall von Leukamie. Arch Pathol 12:37, 1857.
Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance
of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemi a and
normal cytogenetics: a study of the AML study group Ulm. Blood. 2002;100(13):4372 –80.
Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are the main determinants of outcome
in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial
AML HD98 -B. Blood. 2006;108(10):3280 -3288.
Frohling S, Skelin S, Liebisch P, et al. Comparison of cytogenetic and molecular cytogenetic detection
of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin
Oncol 2002; 20(10):2480 -2485
Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from
a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol.
2011;29(10):1364 -1372.
Gaidzik VI, Paschka P, Spath D, et al. TET2 mutations in acute myeloid leukemia (AML): results
from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol.
2012;30(12):1350 – 1357.
Gaidzik VI, Paschka P, Sp ath D, et al. TE T2 mutations in acute myeloid leukemia (AML): results
from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol.
2012;30(12):1350 -1357.
Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger a dult
patients with acute myeloid leukemia: a comprehensive analysis of the AML Study Group (AMLSG).
Blood. 2013;121(23):4769 -4777.
Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are
associated with distinct clinico -pathologic and genetic features. Leukemia. 2016;30(11): 2160 -2168.
Gardin C, Chevret S, Pautas C, et al. Superior long -term outcome with idarubicin compared with high –
dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol.
2013;31(3):321 -327.
Gardin C, Turlure P, Fagot T, et al. Post -remission treatment of elderly patients with acute myeloid
leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter
randomized Acute Leuke mia French Association (ALFA) 9803 trial. Blood. 2007;109(12):5129 -5135.
Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D. The haematopoietic cell
transplantation comorbidity index score is predictive of early death and survival in patien ts over 60
years of age receiving induction therapy for acute myeloid leukaemia.
Br J Haematol. 2007;136(4):624 -627.

191 Goardon N, Marchi E, Atzberger A, et al: Coexistence of LMPP -like and GMP -like leukemia stem
cells in acute myeloid leukemia. Cancer Cell 2 011; 19:138
Godley LA, Larson RA. Therapy -related myeloid leukemia. Semin Oncol. 2008;35(4):418 -429.
Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve
treatment outcomes in acute myeloid leukemia (AML) in older pa tients: the results of the United
Kingdom Medical Research Council AML 11 trial. Blood. 2001;98(5):1302 -1311.
Granfeldt LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary
and therapy -related acute myeloid leukemia: a na tional population -based cohort study. J Clin Oncol.
2015;33(31):3641 -3649.
Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid
leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352(9134):1087 -1092.
Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic haematopoietic stem cell
transplantation: a retrospective analysis. Cancer. 2009;115(20):4715 -4726.
Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 m utations in AML depends
on the location of the mutation. Blood. 2011;118(2):409 -412.
Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA
mutations in a large cohort of younger adult patients with acute myeloid leuke mia: impact of double
CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol.
2010;28(16):2739 -2747.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 2 012; 120(12):2454 -2465.
Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid
leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities
among 5876 younger adult patients tre ated in the United Kingdom Medical Research Council trials.
Blood 2010;116(3):354 -365.
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of
cytogenetic classification in acute myeloid leukemia: determination of prognos tic significance of rare
recurring chromosomal abnormalities among 5876 younger adult patients treated in the United
Kingdom Medical Research Council trials. Blood. 2010;116(3):354 -65.
Grimwade D, Walker H, Harrison G, et al. The predictive value of hierar chical cytogenetic
classification in older adults with acute myeloid leukemia: analysis of 1065 patients entered into the
United Kingdom Medical Research Council AML 11 trial. Blood. 2001;98(5):1312 -1320.
Grimwade D, Hills R, Moorman AV et al. Refinement of cytogenetic classification in AML:
determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5635
younger adults treated in the UK MRC trials [abstract]. Haematologica 2009; 94 suppl 2:217.Abstract
0533
Grimwade D, Walk er H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in
AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92(7):2322 -2333.
Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloi d leukaemia. Best
Pract Res Clin Haematol 2001; 14(3):497 -529.
Groschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes
concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014; 157(2):369 -381

192 Grossmann V, Schni ttger S, Kohlmann A, Eder C, Roller A, Dicker F, et al. A novel hierarchical
prognostic model of AML solely based on molecular mutations. Blood. 2012;120:2963 – 72
Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 ge ne in
acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia.
2008;22:1539 -41.
Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant
karyotype show overlapping biologic, patholo gic, immunophenotypic, and prognostic features. Blood.
2009;114(14):3024 -3032.
Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, et al. Proposals for
standardized protocols for cyto – genetic analyses of acute leukemias, chronic lym phocytic leukemia,
chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
GenesChromosomes. Cancer. 2007;46(5):494 -9.
Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with
myelo dysplastic syndromes. Leukemia. 2014; 28(2):241 -247.
Haferlach T, Stengel A, Eckstein S, et al. The new provisional WHO entity „RUNX1 mutated AML‟
shows specific genetics but no prognostic influence of dysplasia. Leukemia. 2016;30(10): 2109 -2112
Haferlach T. How does one work -up an acute myeloid leukemia patient in the molecular era?
Hematology Education: the education program for the annual congress of the European Hematology
Association 2015;9:47 -56
Hann IM, Stevens RF, Goldstone AH, et al. Randomized co mparison of DAT versus ADE as
induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the
Medical Research Council‟s 10th AML trial (MRC AML10). Blood. 1997;89(7):2311 -2318.
Hansen OP, Pedersen -Bjergaard J, Ellegaard J, et al. Aclarubicin plus cytosine arabinoside versus
daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia:
a Danish national phase III trial. Leukemia. 1991;5(6):510 -516.
Harousseau J -L, Cahn J -Y, Pignon B, et al. Comparison of autologous bone marrow transplantation
and intensive chemotherapy as post -remission therapy in adult acute myeloid leukemia. Blood.
1997;90(8):2978 -2986.
Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification o f neoplastic diseases of
the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting -Airlie
House, Virginia J Clin Oncol 1999;17(12):3835 -3849
Harutyunyan AS, Giambruno R, Krendl C, et al. Germline RBBP6 mutations in familial
myeloproliferative neoplasms. Blood. 2016; 127(3):362 -365
Herve Dombret and Claude Gardin. An update of current treatments for adult acute myeloid leukemia.
Blood . 2016; 127(1): 53 –61.
Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction
chemotherapy in adult patients with acute myeloid leukaemia: a meta -analysis of individual patient
data from randomised controlled trials. Lancet Oncol. 2014;15(9):98 6-996.
Hirschfield H: Zur Kenntnis der Histogenese der granulirten Knochenmarkzellen. Arch Pathol
153:335, 1898.
Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and
cytarabine during induction prolongs surv ival of patients with acute myeloid leukemia: a multicenter,
randomized phase III study. J Clin Oncol. 2012;30(20):2441 -2448.

193 Holtick U, Albrecht M, Chemnitz JM, et al. Bone marrow versus peripheral blood allogeneic
haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane
Database Syst Rev. 2014;4: CD010189.
Horowitz MM, Gale RP, Sondel PM, al. Graft -versus -leukemia reactions after bone marrow
transplantation. Blood. 1990;75(3):555 -562.
Hou HA, Lin LI, Chen CY, Tien HF. R eply to „Heterogeneity within AML with CEBPA mutations;
only CEBPA double mutations, but not single CEBPA mutations are associated with favorable
prognosis‟. Br J Cancer. 2009;101(4): 738 -740.
Hsu TC: Human and Mammalian Cytogenetics: An Historical Perspe ctive . Springer -Verlag, New
York, 1979.
http://www.hctci.org/
Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary
acute myeloid leukemia in a population -based setting: a re port from the Swedish Acute Leukemia
Registry. Am J Hematol. 2015;90(3):208 -214.
Jaglal MV, Duong VH, Bello CM, et al. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG –
M) compared to standard induction in acute myeloid leukemia from myelodysplast ic syndrome after
azanucleoside failure. Leuk Res. 2014;38(4):443 -446.
Jan M, Snyder TM, Ryan M, et al: Clonal evolution of preleukemic hematopoietic stem cells precedes
human acute myeloid leukemia. Sci Transl Med 2012; 149:149ra118.
Jeha S, Giles FJ. Acut e myeloid leukemia, American Society of Hematology Self -Assessment
Program Text Book -2007:243 -252
Jourdan E, Boissel N, Chevret S, et al; French AML Intergroup. Prospective evaluation of gene
mutations and minimal residual disease in patients with core bin ding factor acute myeloid leukemia.
Blood. 2013;121(12):2213 -2223.
Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on
decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood.
2009;113(18):41 79-4187.
Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E et al. Results of intensive
chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high -risk
myelodysplastic syndrome: Predictive prognostic models for outc ome. Cancer. 2006;106(5):1090 –
1098.
Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy -related leukemia and myelodysplastic
syndrome. Hematol Oncol Clin North Am. 1993;7(1):81 -107.
Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia:
prognostic impact and outcome after different treatment strategies. Blood. 2012;119(2):551 -558.
Kelly LM, Gilliland DG: Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002;
3:179
Kern W, Haferlach T, Schnittger S, Hiddem ann W, Schoch C. Prognosis in therapy -related acute
myeloid leukemia and impact of karyotype [letter]. J Clin Oncol. 2004;22(12):2510 -2511.
Khalidi HS, Medeiros LJ, Chang KL, Brynes RK, Slovak ML, Arber DA. The immunophenotype of
adult acute myeloid leukemi a: high frequency of lymphoid antigen expression and comparison of
immunophenotype, French -American -British classification, and karyotypic abnormalities. Am J Clin
Pathol 1998;109(2):211 -220.

194 Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated
with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B -cell antigen
CD19 together with stem cell antigen CD34. Blood. 1992;80(2):470 -477.
Kiyoi H, Yanada M, Ozekia K. Clinical significance of FLT3 in leukemia. Int J Hematol.
2005;82(2):85 -92.
Kleiblova P, Shaltiel IA, Benada J, et al. Gain -offunction mutations of PPM1D/Wip1 impair the p53 –
dependent G1 checkpoint. J Cell Biol. 2013; 201(4):511 -521.
Klepin HD, Geiger AM, Tooze JA, et al. Ger iatric assessment predicts survival for older adults
receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21): 4287 -4294.
Klepin HD . Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia
Hematology Am Soc H ematol Educ Program. 2014(1):8 -13
Knapper S, Hills RK, Cavenagh JD, et al. A randomised comparison of the sequential addition of the
FLT3 inhibitor lestaurtinib (CEP701) to standard first line chemotherapy for FLT3 – mutated acute
myeloid leukemia: The UK experience [abstract]. Blood. 2014;124(21). Abstract 3736.
Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid
leukemia in first complete remission: systematic review and metaanalysis of prospective clinical trial s.
JAMA. 2009;301(22):2349 -2361.
Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a
FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important
prognostic information to cytogen etic risk group and response to the first cycle of chemotherapy:
analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
Blood. 2001;98(6):1752 –9.
Kroger N, Brand R, van Biezen A, et al. Autologous stem cell transpl antation for therapy -related acute
myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2006;37(2):183 -189.
Larson RA, Wernli M, Le Beau MM, et al. Short remission durations in therapy -related leukemia
despite cytogenetic complete respons es to high dose cytarabine. Blood. 1988;72(4):1333 -1339.
Lee JH, Joo YD, Kim H, et al; Cooperative Study Group A for Hematology. A randomized trial
comparing standard versus high -dose daunorubicin induction in patients with acute myeloid leukemia.
Blood. 2 011;118(14): 3832 -3841
Leick MB , Levis MJ . The Future of Targeting FLT3 Activation in AML. Curr Hematol Malig
Rep. 2017 Jun;12(3):153 -167
Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of
multidrug resistance (MDR1) and cytogenetics distinguishe biologic subgroups with remarkably
distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;
89(9):3323 -3329.
Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy
followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):
3294 -3301.
Levis M. FLT3/ITD AML and the law of unintended conseq uences. Blood. 2011; 117(26):6987 –90.
Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med.
2010; 363(25):2424 -2433.

195 Liesveld Jane L. and Marshall A. Lichtman . ACUTE MYELOGENOUS LEUKEMIA . Kaushansky K,
Lichtman MA, Prcha l JT, Levi MM, Press OW, Burns LJ, Caligiuri MA, editors. Williams
Hematology. 9th Edition. McGraw -Hill Education 2016: 1376
Lim ZY, Ingram W, Brand R, et al. Impact of pretransplant comorbidities on alemtuzumab -based
reduced -intensity conditioning allogen eic hematopoietic SCT for patients with high -risk
myelodysplastic syndrome and AML. Bone Marrow Transplant. 2010; 45:633 –639
Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct
somatic mutations. Blood. 2015;125(9) : 1367 -1376.
List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in
patients with poor -risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;
98(12):3212 -3220.
Lo-Coco F, Cicconi L, Breccia M. Current standard treatment of acute promyelocytic leukemia.
British Journal of Haematology. 2016 Mar;172(6):841 -4.
Look AT: Oncogene transcription factors in human acute leukemias. Science1997; 278:1059
Lopez A, de la Rubia J, Martín G, et al. Recent imp rovements in outcome for elderly patients with de
novo acute myeloblastic leukemia. Leuk Res. 2001;25(8):685 -692.
Lowenberg B, Beck J, Graux C, et al; DutchBelgian Hemato -Oncology Cooperative Group
(HOVON); German Austrian AML Study Group (AMLSG); Swiss Gro up for Clinical Cancer
Research Collaborative Group (SAKK). Gemtuzumab ozogamicin as postremission treatment in AML
at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010; 115(13):2586 -2591.
Lowenberg B, Griffin JD, Tallman MS. Acu te myeloid leukemia and acute promyelocytic leukemia.
Hematology Am Soc Hematol Educ Program. 2003;82 -101.
Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High -dose daunorubicin in older patients with
acute myeloid leukemia. N Engl J Med. 2009;361(13):1 235-1248.
Lowenberg B, Ossenkoppele GJ, van Putten W, et al; Dutch -Belgian Cooperative Trial Group for
Hemato -Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical
Cancer Research (SAKK) Collaborative Group. High -dose daunorubicin in o lder patients with acute
myeloid leukemia [published correction in N Engl J Med. 2010; 362(12):1155]. N Engl J Med.
2009;361(13):1235 -1248.
Lowenberg B, Pabst T, Vellenga E, et al; Dutch Belgian Cooperative Trial Group for
HematoOncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative
Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027 -1036.
Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, 417 Graux C, et al. Cytarabine dose
for acute mye loid leukemia. N Engl J Med 2011;364:1027 –36.
Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony –
stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;
349(8):743 -752.
Lowenber g B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission -induction
chemotherapy in elderly patients of 65_ years with acute myeloid leukemia: a randomized phase III
study of the European Organization for Research and Treatment of Cancer Leuke mia Group. J Clin
Oncol. 1989;7(9):1268 -1274.
Lowenberg B. Sense and nonsense of high -dose cytarabine for acute myeloid leukemia. Blood.
2013;121(1):26 -28.

196 Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block
to cell differentiation. Nature. 2012;483(7390):474 -478.
Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute
myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities
underestimated. Blood 2008; 111(8):4329 -4337
Luskin MR, Lee J -W, Fernandez HF, et al. High dose daunorubicin improves survival in AML up to
age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and
FLT3 -ITD mutant AML: updated anal yses from Eastern Cooperative Oncology Trial E1900 [abstract].
Blood. 2014;124(21). Abstract 373.
Mandelli F, Petti MC, Ardia A, et al. A randomised clinical trial comparing idarubicin and cytarabine
to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia: a multicentric study
from the Italian Co -operative Group GIMEMA. Eur J Cancer. 1991;27(6):750 -755.
Marcucci G, Geyer S, Zhao W, et al. Adding KIT inhibitor dasatinib (DAS) to chemotherapy
overcomes the negative impact of KIT mutati on/ over -expression in core binding factor (CBF) acute
myeloid leukemia (AML): results from CALGB 10801 (Alliance) [abstract]. Blood. 2014; 124(21).
Abstract 8.
Marcucci G, Haferlach T, Dohner H Molecular Genetics of Adult Acute Myeloid Leukemia:
Prognosti c and Therapeutic Implications. J Clin Oncol. 2011;29(5):475 -86
Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular
subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group
B study. J Clin Oncol. 2010;28(14):2348 -2355
Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic fa ctors and outcome of core binding factor acute
myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and
Leukemia Group B study. J Clin Oncol. 2005; 23(24):5705 -5717
Martelli MP, Gionfriddo I, Mezzasoma F, et al. Arsen ic trioxide and all -trans retinoic acid target
NPM1 mutant oncoprotein levels and induce apoptosis in NPM1 -mutated AML cells. Blood.
2015;125(22):3455 -3465.
Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita -Hoshi Y, Kim SW, Mori S, Heike Y,
Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y. Comparable antileukemia/lymphoma
effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a
conventional cytoreductive or reduced – intensity regimen. Blood Marrow Transplant 2007;13: 932 -941
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post -remission chemotherapy in adults with acute
myeloid leukemia. N Engl J Med. 1994;33 1(14): 896 -903.
Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain
mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3
internal tandem duplications in patients with acu te myeloid leukemia. Blood. 2007;110(4):1262 –70
Meijer E, Cornelissen JJ. Allogeneic stem cell transplantation in acute myeloid leukemia in first or
subsequent remission: weighing prognostic markers predicting relapse and risk factors for non -relapse
morta lity. Semin Oncol. 2008;35(4): 449 -457.
Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome
in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct
gene and MicroRNA expres sion signatures. J Clin Oncol. 2012;30(25): 3109 -3118.

197 Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, et al. Prevalence and
prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.
Blood. 200 1;97(1):89 –94
Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high -risk subgroup of older
patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood.
2011;118(26):6920 -6929
Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European
LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J
Clin Oncol. 2011;29(10):1373 -1381
Meyer SC, Levine RL. Translational implications of somatic geno mics in acute myeloid leukaemia.
Lancet Oncol 2014; 15(9):e382 -e394.
Mihaela Cîrstea , Adriana Coliță, Bogdan Ionescu et al. Therapy -related myelodysplastic syndrome
after successful treatment of acute promyelocytic leukemia: case report and literature review.
Romanian Journal of Laboratory Medicine. 2017;25(2):165 -179
Milligan DW, Wheatley K, Littlewood T, Craig JIO, Burnett AK. Fludarabine and cytosine are less
effective than standard ADE chemotherapy in high -risk acute myeloid leukemia, and addition of G –
CSF and ATRA are not beneficial: results of the MRC AML -HR randomized trial. Blood. 2 006;
107(12):4614 -4622.
Mohty M, Labopin M, Basara N, et al. Association between the Hematopoietic Cell Transplantation –
Specific Comorbidity Index (CI) and non -relapse mortality (NRM) after reduced intensity
conditioning (RIC) allogeneic stem cell transpl antation (allo -SCT) for acute myeloid leukemia (AML)
in first complete remission (CR1). Blood.2009;114(22) 270, #650
Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high –
dose cytarabine alone as post -remission in tensification therapy for acute myeloid leukemia in adults
under 60 years of age: Cancer and Leukemia Group B study 9222. Blood. 2005;105(9): 3420 -3427.
Morrissette JJ, Bagg A. Acute myeloid leukemia: conventional cytogenetics, FISH, and
moleculocentric me thodologies. Clin Lab Med. 2011;31(4):659 -86
Morton LM, Dores GM, Tucker MA, et al. Evolving risk of therapy -related acute myeloid leukemia
following cancer chemotherapy among adults in the United States, 1975 -2008. Blood.
2013;121(15):2996 -3004.
Mrozek K, Heerema NA, Bloomfield CD Cytogenetics in acute leukemia. Blood Rev , 2004;
18(2):115 -136
Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with
a complex karyotype. Semin Oncol 2008; 358(4):365 -377
Mrzek K, M arcucci G, Nicolet D, et al. Prognostic significance of the European leukemia net
standardized system for reporting cytogenetic and molecular alterations. J Clin Oncol 2012;30:4515 –
23.
Nacheva EP, Grace CD, Brazma D, et al. Does BCR/ABL1 positive acute my eloid leukaemia exist?
Br J Haematol. 2013;161(4):541 -550.
Naegeli O . Ueber rothes Knochenmark und Myeloblasten. Dtsch Med Wochenschr 26:287, 1900.
NCCN Clinical Practice Guidelines in Oncology. Acute myeloid Leukemia: Version 2.2016

198 Neubauer A, Maharry K, Mrozek K, et al. Patients with acute myeloid leukemia and RAS mutations
benefit most from postremission high -dose cytarabine: a Cancer and Leukemia Group B study. J Clin
Oncol 2008; 26:4603 -4609.
Neumann E: Ueber myelogene leukaemie. Berl Klin Wochenschr 15:69, 1878.
Nevill TJ, Hogge DE, Toze CL, et al. Predictors of outcome following myeloablative allo -SCT for
therapy -related myelodysplastic syndrome and AML. Bone Marrow Transplant. 2008;42(10):659 -666.
Ok CY, Patel KP, Garcia -Manero G, et al. Mutational profiling of therapy -related myelodysplastic
syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo
diseases. Leuk Res. 2015;39(3):348 -354.
Olaru D, Campos L, Flandrin P, Nadal N, Duval A, Chautard S et al. (2008) . Multiparametric analysis
of normal and postchemotherapy bone marrow: implication for the detection of leukemia -associated
immunophenotypes. Cytometry Part B, Clin Cytometry. 2008;74:17 –24.
Oran B, Weisdorf D. J. (2012). Survival for older patients with acute myeloid leukemia: A population –
based study. Haematologica 2012 ; 97(12): 1916 -1924.
Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population -based
study. Haematologica. 2012;97(12):1916 – 1924
Ossenkoppele G, L owenberg B. How I treat the older patient with acute myeloid leukemia. Blood.
2015;125(5):767 -774.
Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA -C
and G -CSF in the treatment of patients with high -risk myelodysplastic sy ndromes and AML in elderly
patients. Blood. 2004;103(8):2908 – 2913.
Ossenkoppele GJ, Janssen JJWM, and van de Loosdrecht AA. Risk factors for relapse after allogeneic
transplantation in acute myeloid leukemia. Haematologica 2016;101(1):20 -25
Pabst T, Eyho lzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only
CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.
Br J Cancer. 2009;100(8): 1343 -1346.
Pabst T, Mueller BU: Transcriptional dysre gulation during myeloid transformation in AML.
Oncogene 2007; 26:6829
Pandolfi A, Barreyro L, Steidl U: Concise review: Preleukemic stem cells: Molecular biology and
clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med 2 2013:143
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute
myeloid leukemia. N Engl J Med. 2016;374(23): 2209 -2221.
Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the
International Cancer Genome Consortium. Clinical and biological implications of driver mutations in
myelodysplastic syndromes. Blood. 2013;122(22):3616 -3627, quiz 3699.
Parkin B, Ouillette P, Li Y, et al: Clonal evolution and devolution after chemotherapy in adult acute
myelogenous leukemia. Blood 2013; 121:369
Paschka P, Dohner K. Core -binding factor acute myeloid leukemia: can we improve on HiDAC
consolidation? Hematology (Am Soc Hematol Educ Program). 2013;2013(1):209 -219
Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations
in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid
leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol.
2010;28(22):3 636-3643.

199 Paschka P, Schlenk RF, Herzig J, et al. Unfavorable impact of ASXL1 mutations on achievement of
complete remission and long -term outcome in younger adults with acute myeloid leukemia (AML): A
study of the German -Austrian AMLSG. Onkologie. 2013;3 6(Suppl 7):15. Abstract V67
Paschka P, Schlenk RF, Weber D, et al. Dasatinib (DAS) in combination with chemotherapy and as
maintenance in core -binding factor (CBF) acute myeloid leukemia (AML): a phase Ib/IIa study of the
German -Austrian AML Study Group (A MLSG) [abstract]. Haematologica. 2015;100(s1). Abstract
515.
Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for
induction and recombinant interleukin -2 for maintenance in patients with acute myeloid leukemia age
50 to 70 years: results of the ALFA -9801 study. J Clin Oncol. 2010;28(5): 808 -814
Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for
induction and recombinant interleukin – 2 for maintenance in patients with acute myeloid leukemia age
50 to 70 years: results of the ALFA -9801 study. J Clin Oncol. 2010;28(5): 808 -814.
Petersdorf SH, Rankin C, Head DR, et al. Phase II evaluation of an intensified induction therapy with
standard daunomycin and cytarabine followed by hig h dose cytarabine for adults with previously
untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG -9500). Am J Hematol.
2007;82(12):1056 -1062.
Peterson BA, Brunning RD, Bloomfield CD, et al. Central nervous system involvement in acute
nonlymphocytic leukemia. A prospective study of adults in remission. Am J Med 1987;83(3):464 -470.
Peterson L, Bloomfield CD, Dohner H, Niemeyer C, Godley L. Myeloid neoplasms with germline
predisposition. In: Swerdlow S, Campo E, Harris NL, et al, eds. Worl d Health Organization
Classification of Tumours of Haematopoietic and Lymphoid Tissues. Update to 4th Edition. Lyon,
France: World Health Organization. In press.
Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23(24): 4255 –
4262.
Pfirrmann M, Ehninger G, Thiede C, et al. Prediction of post -remission survival in acute myeloid
leukaemia: a post -hoc analysis of the AML96 trial. Lancet Oncol 2012;13(2):207 -214.
Pharoah PD, Song H, Dicks E, et al; Australian Ovarian Cancer Study Gr oup; Ovarian Cancer
Association Consortium. PPM1D mosaic truncating variants in ovarian cancer cases may be
treatment -related somatic mutations. J Natl Cancer Inst. 2016;108(3):djv347.
Pileri SA, Ascani S, Cox MC, et al. Myeloid sarcoma: clinico -pathologic , phenotypic and cytogenetic
analysis of 92 adult patients. Leukemia 2007;21(2):340 -350.
Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid
neoplasms. Cancer Cell. 2015;27(5): 658 -670.
Pratcorona M, Abbas S, San ders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia:
prevalence and prognostic value. Haematologica. 2012;97(3):388 -392
Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3 -mutant allelic burden and
clinical status are predicti ve of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425 –32
Prebet T, Bertoli S, Delaunay J, et al. Anthracycline dose intensification improves molecular response
and outcome of patients treated for core binding factor acute myeloid leukemia. Haem atologica.
2014;99(10): e185 -e187.
Provan D, Baglin T, Dokal I et al. Acute myeloblastic Leukaemia, Oxford Handbook of Clinical
Hematology, 4th edition, 2015:124 -136

200 Richard F. Schlenk Post-remission therapy for acute myeloid leukemia . Haematologica 2014; 99(11):
1663 -1670
Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, 347 et al. Core binding factor
acute myeloid leukemia and c -KIT mutations. Oncol Rep 2013;29:1867 –72.
Rollig C, Bornhäuser M, Kramer M, et al. Allogeneic Stem -Cell Transpla ntation in Patients With
NPM1 -Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No -Donor
Analysis of Patients After Upfront HLA Typing Within the SAL -AML 2003 Trial. J Clin Oncol.
2015;33(5):403 -410
Rollig C, Müller -Tidow C, Hüttmann A et al. Sorafenib Versus Placebo in Addition to Standard Therapy in
Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the
Randomized Placebo -Controlled SAL -Soraml Trial. Blood 2014 ;124:6 .
Roug AS, Hansen MC , Nederby, Hokland P. Diagnosing and following adult patients with acute
myeloid leukaemia in the genomic age British Journal of Haematology 2014;167(2):162 –176
Rowley JD, Olney HJ. International Workshop on the relationship of prior therapy to balanced
chromosome aberrations in therapy -related myelodysplastic syndromes and acute leukemia: overview
report. Genes Chromosomes Cancer. 2002;33(4):331 -345.
Ruark E, Snape K, Humburg P, et al. Breast and Ovarian Cancer Susceptibility Collaboration;
Wellcome Trust Case Control Consortium. Mosaic PPM1D mutations are associated with
predisposition to breast and ovarian cancer. Nature. 2013;493(7432):406 -410.
Rucker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia
with compl ex karyotypes using microarray -based molecular characterization. J Clin Oncol
2006; 24(24):3887 -3894
Sabine Kayser S, Konstanze Döhner K, Jürgen Krauter J, Claus -Henning Köhne CH, Heinz A. Horst
HA, Gerhard Held G et al. The impact of therapy -related acute myeloid leukemia (AML) on outcome in
2853 adult patients with newly diagnosed AML. Blood 2011; 117:2137 -2145.
Schetelig J, Bornhauser M, Schmid C, et al. Matched unrelated or matched sibling donors result in
comparable survival after allogeneic stemcell tr ansplantation in elderly patients with acute myeloid
leukemia: a report from the Cooperative German Transplant Study Group. J Clin
Oncol. 2008;26(32):5183 -5191.
Schlenk RF, Benner A, Krauter J, et al. Individual patient data -based meta -analysis of patients aged 16
to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid
Leukemia Intergroup. J Clin Oncol. 2004; 22(18):3741 -3750.
Schlenk RF, Dohner H. Genomic applications in the clinic: use in treatment paradigm of acut e
myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2013;2013:324 -330.
Schlenk RF, Dohner K, Kneba M, et al. Gene mutations and response to treatment with all -trans
retinoic acid in elderly patients with acute myeloid leukemia. Results from the AML SG trial AML
HD98B. Haematologica. 2009;94(1):54 -60.
Schlenk RF, Dohner K, Krauter J, et al. All -trans retinoic acid improves outcome in younger patients
with nucleophosmin -1 mutated acute myeloid leukemia. Results of the AMLSG 07 -04 randomized
treatment trial [abstract]. Blood. 2011;118(21). Abstract 80.
Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal
acute myeloid leukemia. N Engl J Med 2008;358:1909 –1918.

201 Schlenk RF, Dohner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem -cell
transplantation from matched related and matched unrelated donors in younger adults with high -risk
acute myeloid leukemia: German -Austrian trial AMLHD98A. J Clin Oncol. 2010;28(30):4642 -4648.
Schlenk RF, Fro hling S, Hartmann F, et al. Intensive consolidation versus oral maintenance therapy in
patients 61 years or older with acute myeloid leukemia in first remission: results of second
randomization of the AML HD98 -B treatment trial [letter]. Leukemia. 2006;20( 4):748 -750.
Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3 –
ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441 -3449
Schlenk RF, Taskesen E, van Norden Y, et al. Th e value of allogeneic and autologous hematopoietic
stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant
CEBPA. Blood. 2013;122(9): 1576 -1582.
Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Ana lysis of FLT3 length
mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype,
and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual
disease. Blood. 2002;100(1):59 –66
Schoc h C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic
parameter in therapy -related acute myeloid leukemia (t -AML): an analysis of 93 patients with t -AML
in comparison to 1091 patients with de novo AML. Leukemia. 2004;1 8(1):120 -125.
Schulz E, Valentin A, Ulz P, et al. Germline mutations in the DNA damage response genes BRCA1,
BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Genet.
2012;49(7):422 -428.
SEER Cancer Statistics Review 1975 –2009 . Available from: http://seer.
cancer.gov/archive/csr/1975_2009_pops09/index.html. Accessed August 20, 2012.
Shaffer LG, McGowan -Jordan J, Schmid M. ISCN 2013: An International System for Human
Cytogenetic Nomenclature (2013): Recommendations of the Intern ational Standing Committee on
Human Cytogenetic Nomenclature. Basel, Switzerland: 2013: 78 -79
Shigesada K, van de Sluis B, Liu PP. Mechanism of leukemogenesis by the inv(16) chimeric gene
CBFB/PEBP2B -MHY11. Oncogene 2004; 23(24):4297 -4307
Shih AH, Chung SS , Dolezal EK, et al. Mutational analysis of therapy -related myelodysplastic
syndromes and acute myelogenous leukemia. Haematologica. 2013; 98(6):908 -912.
Shlush LI, Zandi S, Mitchell A, et al: Identification of pre -leukaemic haematopoietic stem cells in
acute leukaemia. Nature 2014; 506:328.
Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for
treatment of high -risk acute leukemia: the effect of leukemic burden, donor HLAmatching, and
marrow cell dose. Blood. 1997 ; 89(11):4226 -4235.
Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission
and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern
Cooperative Oncology Group Study. Blood. 2000 ; 96(13):4075 -4083
Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission
and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern
Cooperative Oncology Group study. Blood 2000; 96(13): 4075 -4083
Smith SM, Le Beau MM, Huo D, et al. Clinical cytogenetic associations in 306 patients with therapy –
related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood.
2003;102(1):43 -52.

202 Sorror M, Appelbaum FR. Risk asses sment before allogeneic hematopoietic transplantation for older
adults with acute myeloid leukemia. Expert Review of Hematology 2013;6(5): 547-562.
Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation -comorbidity index and
Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic
nonmyeloablative hematopoietic cell transplantation. Cancer. 2008; 112:1992 –2001.
Sorror ML, Giralt S, Sandmaier BM, de Lima M, Shahjahan M, Maloney DG, Deeg HJ, Appe lbaum
FR, Storer B, Storb R. Hematopoietic cell transplantation -specific comorbidity index as an outcome
predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC
experiences. Blood 2007;110: 4608 -4613
Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT) -specific comorbidity
index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106 (8):2912 -2919
Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity -age index: a clinical measure of biologic age
before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29): 3249 -3256.
Sorror ML , Maris MB , Storer B , Sandmaier BM , Diaconescu R , Flowers C et al Comparing
morbidity and mortality of HLA -matched unrelated donor hematopoietic cell transplantation after
nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.
Blood. 2004;104(4):961 -8
Stein EM. Molecularly targeted therapies for acute myeloid leukemia. Am Soc Hematol Educ
Program. 2015:579 -583
Stone R, Mandrekar S, Sanford BL, Geyer S, Bloomfield CD, Dohner K, et al. The multi -kinase
inhibitor midostaurin (M) prolongs survival compare d with placebo (P) in combination with
daunorubicin (D)/cytarabine (C) induction (ind), high -dose C consolidation (consol), and as
maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18 –
60 with FLT3 mutations (mut s): an international prospective randomized (rand) P -controlled double –
blind trial (CALGB 10603/ RATIFY [alliance]). Blood. 2015;126:6. The phase III RATIFY trial of
midostaurin has led to an FDA breakthrough designation of this drug for AML.
Stone RM, Ber g DT, George SL, et al. Post -remission therapy in older patients with de novo acute
myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate -dose cytarabine with
standard -dose cytarabine. Blood. 2001;98(3):548 -553.
Suciu S, Mandelli F, d e Witte T, et al. Allogeneic compared with autologous stem cell transplantation
in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first
complete remission (CR1): an intention -to-treat analysis of the EORTC/GIMEMA AML -10 trial.
Blood. 2003;102(4):1232 -1240.
Swisher EM, Harrell MI, Norquist BM, et al. Somatic mosaic mutations in PPM1D and TP53 in the
blood of women with ovarian carcinoma. JAMA Oncol. 2016;2(3):370 -372.
Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol
Educ Program. 2012;2012:43 -8
Takeyama K, Seto M, Uike N, et al. Therapy -related leukemia and myelodysplastic syndrome: a large –
scale Japanese study of clinical and cytogenetic features as well as prognostic facto rs. Int J Hematol.
2000;71(2):144 -152.
Tallman MS, Dewald GW, Gandham S, et al. Impact of cytogenetics on outcome of matched unrelated
donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete
remission. Blood. 2007;110(1):409 -417.

203 Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute
myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood.
2009;114(26):5352 -5361.
Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and
gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal
AML patients: further evidence for CEBPA double mutant AML as a distinctive disease e ntity. Blood.
2011;117(8): 2469 -2475.
Taskesen E, Havermans M, van Lom K, et al. Two splice -factor mutant leukemia subgroups
uncovered at the boundaries of MDS and AML using combined gene expression and DNAmethylation
profiling. Blood. 2014;123(21): 3327 -3335.
Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3 –
activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes
and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326 –35.
Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in
acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889 -2896
Thomas ED, Buckner CD, Banaji M, et al: One hundred patients with acute leukemia t reated by
chemotherapy, total body irradiation, and allogeneic bone marrow transplantation. Blood 49:511,
1977.
Turhan AG, Lemoire FB, Debert C, et al: Highly purified primitive hematopoietic stem cells are PML –
RARA negative and generate nonclonal progenit ors in acute promyelocytic leukemia. Blood
1995; 85:2154
Van Lom K, Hagenmeijer A, Vandekerckhove F, et al: Clonality analysis of hematopoietic cell
lineages in acute myeloid leukemia and translocation (8;21): Only myeloid cells are part of malignant
clone . Leukemia1997; 11:202
Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis.
Leukemia. 2013;27(9):1861 -1869.
Vardiman JW, Brunning AD, Arber DA, Le Beau MM, Porwit A, Tefferi A. Introduction and
overview of the cl assification of the myeloid neoplasms, Swerdlow S, Campos E, Lee Harris NL, Jaffe
ES, Stefano PA, Stein H, et al, editors. WHO Classification of tumours of haematopoietic and
lymphoid tissues: Lyon, France: International Agency for Research on Cancer. 2008 :19-30
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the
myeloid neoplasms. Blood 2002;100(7):2292 -2302.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO)
classifi cation of myeloid neoplasms and acute leukemia: rationale and important changes. Blood
2009;114(5):937 -951.
Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic
and lymphoid tissues: an overview with emphasis on t he myeloid neoplasms. Chem Biol Interact
2010;184(1 -2):16 -20.
Vogler WR, Velez -Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and
daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer
Study Gro up study. J Clin Oncol. 1992;10(7): 1103 -1111.
Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly
diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment
assignment. J Clin Oncol. 2011; 29(33):4417 -4423.

204 Walter RB, Othus M, Burnett AK, et al. Significance of FAB subclassification of “acute myeloid
leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood.
2013;121(13):2424 -2431.
Ward PS, Patel J, Wise DR, et al. The common feature of leukemia associated IDH1 and IDH2
mutations is a neomorphic enzyme activity converting alpha -ketoglutarate to 2 -hydroxyglutarate.
Cancer Cell. 2010;17(3):225 -234.
Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high -dose versus
standard -dose cytosine arabinoside with daunorubicin in patients with previously untreated acute
myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88(8):2841 -2851.
Welch JS, Ley TJ, Link DC, et al: The origin and evolution of mutations in acute myeloid leukemia.
Cell 2012; 150:264
Weltermann A, Fonatsch C, Haas OA, et al. Impact of cytogenetics on the prognosis of adults with de
novo AML in first relapse. Leukemia. 2004;18(2):293 -302.
Wiernik PH, Banks PLC, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction
and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood.
1992;79(2):313 -319.
Wiernik PH. Extramedullary manifestations o f adult leukemia. London: BC Decker; 2001.
Willekens C, Blanchet O, Renneville A et al. Prospective Long -Term Minimal Residual Disease
Monitoring Using RQ -PCR In RUNX1 -RUNX1T1 -Positive Acute Myeloid Leukemia: Results Of The
French CBF -2006 Trial. Haema tologica 2016; 101(3): 328-335.
Willemze R, Suciu S, Meloni G, et al. High -dose cytarabine in induction treatment improves the
outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the
EORTC -GIMEMA AML -12 trial. J Clin Oncol. 2014;32(3):219 -228.
Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of
therapy -related acute myeloid leukaemia. Nature. 2015;518(7540):552 -555.
Wouters BJ, Lowenberg B, ErpelinckVerschueren CA, van Putten WL, Valk PJ, Delwel R. Double
CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia
with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood.
2009;113(13): 3088 -3091.
Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H, et al. Tandem duplication of the FLT3 gene
is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in
myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children . Br J Haematol.
1999;105(1):155 –62.
Yakoub -Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for
therapy -related myelodysplastic syndrome and acute myeloid leukemia: a long -term study of 70
patients –report of the French Society of Bone Marrow Transplantation. J Clin Oncol. 2000;18(5):963 –
971.
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of
D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97 (8):
2434 –9.
Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives
leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25(4): 415 -427

205 Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic he matopoietic stem cell transplantation
depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis.
Cancer. 2005;103(8):1652 -1658.
Yang X, Sexauer A, Levis M. Bone marrow stroma -mediated resistance to FLT3 inhibitors i n FLT3 –
ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol.
2013;164:61 –72.
Yates JW, Wallace HJ, Ellison RR, Holland JF: Cytosine arabinoside and daunorubicin therapy in
acute non -lymphocytic leukemia. Cancer Chem other Rep 52:485, 1973.
Yin JA, O'Brien MA, Hills RK et al. Minimal residual disease monitoring by quantitative RT -PCR in core
binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML –
15 trial. Blood 2012; 120(14); 2826 -2835.
Zajkowicz A, Butkiewicz D, Drosik A, Giglok M, Suwinski R, Rusin M. Truncating mutations of
PPM1D are found in blood DNA samples of lung cancer patients. Br J Cancer. 2015;112(6): 1114 –
1120.
Zeidan AM, Gore SD. New strategies in acute promyelocytic leukemia: Moving to an Entirely Oral,
Chemotherapy -Free Upfront Management Approach. Clinical Cancer Research. 2014 Oct;
20(19):4985 -93.
Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and
hematologic malignancy. Nat Genet. 2015; 47(2):180 -185.